Redirect Notice

Looks like you clickedhttp://www.gilead.com/news/press-releases/2013/10/gilead-to-stop-phase-3-study-116-of-idelalisib-in-chronic-lymphocytic-leukemia-early-because-of-positive-riskbenefit

If you do not want to visit that page, you can close this browser tab.